CompletedNCT01108393
Agomelatine or placebo for obsessive-compulsive symptoms
About this title
Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder
Read the official source — NCT01108393Researchers compared Agomelatine A and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Medication studyAges 18–65Israel
Understand this study
What did researchers investigate?
Researchers compared Agomelatine A and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Tel HaShomerSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 74
- Sponsor
- Institut de Recherches Internationales Servier
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01108393
- Official title
Show the full official title
Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tel HaShomer
Questions about this study
What did researchers investigate?
Researchers compared Agomelatine A and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Agomelatine A and Placebo.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
